Dernières publications
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
Int J Cancer. 2019 Mar 1;144
Cortesi L, Canossi B, Battista R, Pecchi A, Drago A, Dal Molin C, Toss A, De Matteis E, Marchi I, Torricelli P, Cascinu S.
Lire la suite
GISCAD investigators Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Eur J Cancer. 2017 Sep;83:106-115.
Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F
Lire la suite
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain.
Journal of Clinical Oncology 2016; 34: 436–42
Bandieri E, Romero M, Ripamonti CI, et al.
Lire la suite
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes.
Pancreatology 2015; 15: 8–12
Hidalgo M, Cascinu S, Kleeff J, et al
Lire la suite
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, noninferiority phase 3 study.
The Lancet Oncology 2014; 15:
Price TJ, Peeters M, Kim TW, et al
Lire la suite
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Journal of Clinical Oncology 2011; 29: 2011–9
Van Cutsem E, Köhne C-H, Láng I, et al
Lire la suite
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
Journal of Clinical Oncology 2009; 27: 2622–9
Loupakis F, Pollina L, Stasi I, et al.
Lire la suite
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer:a randomised, multicentre, phase II trial.
The Lancet Oncology 2008; 9: 39–44
Cascinu S, Berardi R, Labianca R, et al.
Lire la suite
Nuclear factorkB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Journal of Clinical Oncology 2007; 25: 3930–5
Scartozzi M, Bearzi I, Pierantoni C, et al
Lire la suite
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Journal of Clinical Oncology 2006; 24: 1883–91
Ruzzo A, Graziano F, Kawakami K, et al.
Lire la suite
Prognostic role of interleukin-1ß gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer.
Journal of Clinical Oncology 2005; 23: 2339–45
Graziano F, Ruzzo A, Santini D, et al
Lire la suite
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies.
Journal of Clinical Oncology 2004; 22: 4720–6
Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S.
Lire la suite
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer.
Oncogene 2002; 21: 8192–5
Humar B, Graziano F, Cascinu S, et al.
Lire la suite
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial.
Journal of Clinical Oncology 1995; 13: 26–32
Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G.
Lire la suite
Recombinant human erythropoietin treatment in cisplatinassociated anemia: A randomized, double-blind trial with placebo.
Journal of Clinical Oncology 1994; 12: 1058–62
Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G.
Lire la suite